253 related articles for article (PubMed ID: 21304503)
1. Integrating pharmacogenetics into gemcitabine dosing--time for a change?
Ciccolini J; Mercier C; Dahan L; André N
Nat Rev Clin Oncol; 2011 Feb; 8(7):439-44. PubMed ID: 21304503
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective.
Ciccolini J; Serdjebi C; Peters GJ; Giovannetti E
Cancer Chemother Pharmacol; 2016 Jul; 78(1):1-12. PubMed ID: 27007129
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology and pharmacogenetics of gemcitabine.
Wong A; Soo RA; Yong WP; Innocenti F
Drug Metab Rev; 2009; 41(2):77-88. PubMed ID: 19514966
[TBL] [Abstract][Full Text] [Related]
4. The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C.
Metharom E; Galettis P; Manners S; Jelinek M; Liauw W; de Souza PL; Hoskins JM; Links M
Asia Pac J Clin Oncol; 2011 Mar; 7(1):65-74. PubMed ID: 21332653
[TBL] [Abstract][Full Text] [Related]
5. High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine.
Raynal C; Ciccolini J; Mercier C; Boyer JC; Polge A; Lallemant B; Mouzat K; Lumbroso S; Brouillet JP; Evrard A
Ther Drug Monit; 2010 Feb; 32(1):53-60. PubMed ID: 20010457
[TBL] [Abstract][Full Text] [Related]
6. Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.
Mitra AK; Kirstein MN; Khatri A; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK
Pharmacogenomics; 2012 Jul; 13(9):1009-21. PubMed ID: 22838949
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism.
Sugiyama E; Kaniwa N; Kim SR; Kikura-Hanajiri R; Hasegawa R; Maekawa K; Saito Y; Ozawa S; Sawada J; Kamatani N; Furuse J; Ishii H; Yoshida T; Ueno H; Okusaka T; Saijo N
J Clin Oncol; 2007 Jan; 25(1):32-42. PubMed ID: 17194903
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors.
Danesi R; Altavilla G; Giovannetti E; Rosell R
Pharmacogenomics; 2009 Jan; 10(1):69-80. PubMed ID: 19102717
[TBL] [Abstract][Full Text] [Related]
9. Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative results.
Mercier C; Evrard A; Ciccolini J
J Clin Oncol; 2007 Oct; 25(30):4855; author reply 4855-6. PubMed ID: 17947739
[No Abstract] [Full Text] [Related]
10. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
[TBL] [Abstract][Full Text] [Related]
11. Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
Cohen R; Preta LH; Joste V; Curis E; Huillard O; Jouinot A; Narjoz C; Thomas-Schoemann A; Bellesoeur A; Tiako Meyo M; Quilichini J; Desaulle D; Nicolis I; Cessot A; Vidal M; Goldwasser F; Alexandre J; Blanchet B
Br J Clin Pharmacol; 2019 Jun; 85(6):1227-1238. PubMed ID: 30701582
[TBL] [Abstract][Full Text] [Related]
12. FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.
Serdjebi C; Gagnière J; Desramé J; Fein F; Guimbaud R; François E; André T; Seitz JF; Montérymard C; Arsene D; Volet J; Abakar-Mahamat A; Lecomte T; Guerin-Meyer V; Legoux JL; Deplanque G; Guillet P; Ciccolini J; Lepage C; Dahan L
PLoS One; 2015; 10(8):e0135907. PubMed ID: 26308942
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics and pharmacoepigenetics of gemcitabine.
Candelaria M; de la Cruz-Hernández E; Pérez-Cárdenas E; Trejo-Becerril C; Gutiérrez-Hernández O; Dueñas-González A
Med Oncol; 2010 Dec; 27(4):1133-43. PubMed ID: 19902390
[TBL] [Abstract][Full Text] [Related]
14. Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
Mercier C; Dahan L; Ouafik L; André N; Ciccolini J
Eur J Clin Pharmacol; 2010 Sep; 66(9):959-60. PubMed ID: 20563566
[No Abstract] [Full Text] [Related]
15. Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing.
Giovannetti E; Tibaldi C; Falcone A; Danesi R; Peters GJ
J Clin Oncol; 2010 May; 28(14):e221-2; author reply e223-5. PubMed ID: 20351322
[No Abstract] [Full Text] [Related]
16. SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.
Khatri A; Williams BW; Fisher J; Brundage RC; Gurvich VJ; Lis LG; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK; Kirstein MN
Br J Cancer; 2014 Jan; 110(2):304-12. PubMed ID: 24300978
[TBL] [Abstract][Full Text] [Related]
17. Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients.
Ueno H; Kaniwa N; Okusaka T; Ikeda M; Morizane C; Kondo S; Sugiyama E; Kim SR; Hasegawa R; Saito Y; Yoshida T; Saijo N; Sawada J
Br J Cancer; 2009 Mar; 100(6):870-3. PubMed ID: 19293806
[TBL] [Abstract][Full Text] [Related]
18. Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations.
Elnaggar M; Giovannetti E; Peters GJ
Curr Pharm Des; 2012; 18(19):2811-29. PubMed ID: 22390765
[TBL] [Abstract][Full Text] [Related]
19. Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.
Ding X; Chen W; Fan H; Zhu B
Gene; 2015 Mar; 559(1):31-7. PubMed ID: 25582275
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
Maring JG; Wachters FM; Slijfer M; Maurer JM; Boezen HM; Uges DR; de Vries EG; Groen HJ
Eur J Clin Pharmacol; 2010 Jun; 66(6):611-7. PubMed ID: 20213492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
